{"id":"W4286297240","doi":"10.1200/jco.2022.40.16_suppl.5574","title":"Integrated safety summary of single-agent mirvetuximab soravtansine in patients with folate receptor α (FRα)-positive recurrent ovarian cancer: Phase 1 and 3 clinical trials.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"ImmunoGen","keywords":"Medicine; Tolerability; Ovarian cancer; Internal medicine; Adverse effect; Gastroenterology; Population; Oncology; Phases of clinical research; Folate receptor; Nausea; Cancer; Toxicity; Surgery; Cancer cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003522957,0.0007169832,0.001625071,0.0005000541,0.0002573392,0.0009704516,0.0005554474,0.0008554999,0.003619109],"category_scores_gemma":[0.003432925,0.0003682458,0.002499813,0.0006154974,0.0003015286,0.0005536822,0.0003158434,0.001024601,0.0005374518],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001087681,"about_ca_system_score_gemma":0.001367778,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004669976,"about_ca_topic_score_gemma":0.001185269,"domain_scores_codex":[0.998776,0.0007246765,0.0001207399,0.0001591807,0.0001300675,0.00008939582],"domain_scores_gemma":[0.9981224,0.0004171918,0.0009150768,0.0001190817,0.0001745006,0.0002516958],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6500751,0.004820787,0.03187445,0.004363775,0.01516153,0.0003153495,0.0002828036,0.003334396,0.02032835,0.000308548,0.004511928,0.264623],"study_design_scores_gemma":[0.3131107,0.4987209,0.1434978,0.0006099321,0.01622854,0.001226429,0.0001685493,0.002391141,0.007455821,0.0005494105,0.01597291,0.00006780217],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9459797,0.03545466,0.003272693,0.0006207083,0.0001507471,0.004278722,0.005582158,0.0002224979,0.00443808],"genre_scores_gemma":[0.9861092,0.006136891,0.001168609,0.0004784966,0.0001675413,0.001496784,0.003564665,0.00003065668,0.0008472532],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003619109,"threshold_uncertainty_score":0.0186314,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.148324719637099,"score_gpt":0.4735685532588019,"score_spread":0.3252438336217029,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}